Monte Rosa Therapeutics (GLUE) Accounts Payables (2020 - 2026)

Monte Rosa Therapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $7.9 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 21.74% year-over-year to $7.9 million; the TTM figure through Mar 2026 stood at $7.9 million (up 21.74% YoY), while the FY2025 annual figure was $3.6 million, down 79.38% from the prior year.
• Accounts Payables for Q1 2026 stood at $7.9 million, up from $3.6 million in the prior quarter.
• The five-year high for Accounts Payables was $17.2 million in Q4 2024, with the low at $3.6 million in Q4 2025.
• The 5-year median for Accounts Payables is $6.5 million (2025), against an average of $7.5 million.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables surged 758.8% in 2022, then tumbled 79.38% in 2025.
• Monte Rosa Therapeutics' Accounts Payables stood at $7.9 million in 2022, then surged by 41.85% to $11.2 million in 2023, then soared by 54.37% to $17.2 million in 2024, then sank by 79.38% to $3.6 million in 2025, then soared by 122.54% to $7.9 million in 2026.
• Business Quant data shows GLUE's Accounts Payables at $7.9 million in Q1 2026, $3.6 million in Q4 2025, and $14.5 million in Q3 2025.